AGITG Trial news: The AGITG currently has 14 studies open to recruitment and 14 studies in follow up.
The table below details the AGITG trials that are currently accruing patients.
Recruited | Target | Date of First Site Open (ANZ) | Number of Sites Open | End of Recruitment | |
ACME ABC (Biliary tract cancer) | 0 | 50-75 | 23 February 2023 | 1 | November 2024 |
ASCEND (Pancreatic cancer) | 76 | 125 | 13 April 2022 | 19 | April 2024 |
GENESCREEN 5-FU (Pan Tumour) | 104 | 100 | 1 February 2021 | 4 | April 2025 |
ICEMELT (Gastrointestinal) | 160 | 200 | 9 December 2020 | 2 | November 2025 |
INTEGRATE IIb (Gastro-oesophageal cancer) | 312 | 450 | 28 April 2021 | 22 | April 2023 |
MASTERPLAN (Pancreatic cancer) | 39 | 120 | 01 October 2019 | 14 | October 2023 |
MASTERPLAN Microbiome (Pancreatic cancer) | 7 | 60 | July 2022 | 4 | February 2024 |
NEO-IMPACT (Pancreatic cancer) | 10 | 20 | 13 May 2022 | 3 | June 2024 |
OXTOX (Colorectal cancer) | 23 | 100 | 18 December 2020 | 10 | December 2023 |
PALEO (Oesophageal cancer) | 6 | 54 | 3 December 2021 | 1 | May 2023 |
RANDOMS (Pancreatic cancer) | 14 | 60 | 14 December 2020 | 3 | February 2024 |
RENO (Rectal cancer) | 68 | 125 | 21 January 2019 | 9 | January 2024 |
RESOLUTE (Colorectal Cancer) | 1 | 75 | 14 December 2021 | 7 | December 2024 |
SPAR (Rectal cancer) | 122 | 222 | 13 April 2018 | 19 | May 2023 |
SSGXXII (Gastro-intestinal Stromal Tumour) | 10 | 15-20 | 17 February 2022 | 8 | March 2023 |
VADER (Colorectal cancer) | 0 | 90 | 23 January 2023 | 1 | June 2024 |